ABSTRACT

Background: Gynecological cancers have been shown to contribute overwhelmingly to gynecological mortality worldwide, particularly in developing countries. An in‑depth study of the patterns of the distribution will help to elucidate the estimates of the disease burden in University of Abuja Teaching Hospital (UATH).

Objectives: The aim of this study was to determine the pattern and relative frequencies of gynecological cancers at UATH.

Materials and Methods: Case notes of patients managed for gynecological cancers at UATH over a 5-year period from January 1, 2014 to December 31, 2018 were retrieved. Relevant data on age, parity, and type of cancer, clinical, surgical, and histopathological diagnosis were collated using a proforma and analyzed using Statistical Package for the Social Sciences (SPSS).

Result: A total of 167 gynecological cancer cases of 3030 gynecological admissions were seen during the period putting its prevalence at 5.5%. The most common gynecologic cancer was cervical cancer that constituted (88) 52.7% of the cases; ovarian 47 (28.1%), endometrial 17 (10.2%), choriocarcinoma 11 (6.6%), and vulva cancers 4 (2.40%) are not so common. The mean age and parity at presentation are cervical cancer (55.50 ± 12.71 and 4.41 ± 2.05), ovary (42.34 ± 14.91 and 2.94 ± 2.11), uterus (50.54 ± 15.18 and 3.39 ± 2.25), and vulva (63.50 ± 15.09 and 5.50 ± 2.38), respectively. The overall mean age for all cancers is 51.16 ± 14.95 and overall parity is 3.85 ± 2.21. Majority presented in advanced stage of the disease; the most common cause of death is renal failure.

Conclusion: The burden of gynecological cancers is high, although cervical cancer is on downward trend in our environment and most cancer cases came as late presentations.

Key words: Abuja; cervical cancer; choriocarcinoma; gynecological cancers; ovarian cancer.

Introduction

Genital tract malignancies are among the leading causes of cancer-related deaths globally and it is responsible for approximately 10% of all malignancies in women.[1] These cancers are seen worldwide but their patterns and frequencies of distributions vary from one place to another.[2] It accounted for 25% of all new cancers diagnosed in women aged up to 65 years compared with 16% in the developed world according to a global report shown by the International Agency for Research on Cancer.[3] Likewise, developing countries accounted for 820,265 cases (77.7%) of global estimates for new cases of the most common gynecological cancers, including cervical, corpus, and ovarian cancers,

Address for correspondence: Dr. H. I. Abdullahi, Department of Obstetrics and Gynaecology, University of Abuja Teaching, Abuja, Nigeria. Email: ibrahimhabiba@yahoo.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRMedknow_reprints@wolterskluwer.com

How to cite this article: Abdullahi HI, Ayogu ME. Pattern and relative frequencies of gynecological malignancies at the University of Abuja Teaching Hospital, Abuja. Trop J Obstet Gynaecol 2020;37:177-81.

Received: 14-01-2020 Accepted: 13-03-2020
Published Online: 14-08-2020
Ovarian malignancy is a second major cause of death from female genital tract malignancies. Patients with ovarian cancer present with advanced stages of the disease in 75% of the cases due to nonspecific symptoms and there is no standard screening technique for early diagnosis of ovarian cancer. Ovarian cancer diagnosis still poses a great challenge because of the intraabdominal disadvantaged position of the ovary and its highest case fatality rate among gynecological cancers worldwide is due partly to its late presentation. A study conducted in Ibadan, Nigeria revealed that it represents 16.3% of the genital tract cancers. Globally, there are more than 200,000 new cases of ovarian cancer diagnosed with approximately 6.6 new cases per 100,000 women annually. Greater awareness of symptoms potentially associated with ovarian cancer might lead to earlier diagnosis, which might improve survival.

Currently, endometrial cancer is the most common genital tract malignancy in North America and Western Europe. It is probably the third most common malignant tumor of the genital tract in sub-Saharan Africa and accounted for 4%–11% of all genital tract cancers in a recent study conducted in Nigeria. They are more common among postmenopausal women and vaginal bleeding with or without discharge appeared to be the common presentation.

On the contrary, vulva cancer is a rare disease accounting for 3%–5% of gynecological cancers worldwide and remains an important disease affecting sexuality. It accounted for 2.1% of all gynecological malignancies in an earlier study conducted in Ghana and over 80% of cases occur in women more than 55 years of age. It is primarily a disease of elderly women, occurring in women over 60 years of age but has been observed in premenopausal women as well.

Choriocarcinoma is a malignant variant of gestational trophoblastic disease with a highly aggressive biologic behavior and sensitive to chemotherapy. It constitutes approximately 0.6% of all cancers of the female reproductive system. In 2002, there were approximately 5800 cases reported worldwide, the vast majority occurring in less developed regions. In the USA, the incidence is 1 in 40,000 pregnancies, whereas it is 0.80 and 0.87 per 1000 deliveries in Ghana and Nigeria, respectively.

Despite such a frequency and incidence, there is paucity of knowledge and data regarding this dreadful condition. This study aimed at evaluating the relative frequencies and pattern of female genital tract malignancies in Abuja, Nigeria.

**Study population**

The study population comprised all the patients who had gynecological cancer at University of Abuja Teaching Hospital (UATH) during the study period.

**Inclusion criteria**

The inclusion criteria of the study were all patients with complete available data/variable of interest within the study period.

**Exclusion criteria**

The exclusion criteria of the study were patients whose data or variable of interest was not complete during data collection and those without histological diagnoses.

**Study period**

The study was commenced after obtaining approval for the proposal from the institution health research ethics committee. The study period was from January 1, 2014 to December 31, 2018.

**Materials and Methods**

This was a retrospective descriptive study of patients admitted for gynecological cancers at UATH, Abuja. The case notes of patients admitted for gynecological cancers over a 5-year period from January 1, 2014 to December 31, 2018 were retrieved. Relevant data on age, parity, and type of cancer, clinical, surgical and histopathological diagnosis were collated using a proforma. The cases of choriocarcinoma were diagnosed based on clinical features and confirmed by biochemical test. The data obtained were analyzed...
using Statistical Package for the Social Sciences (SPSS) software program, version 22.0 (IBM Corp., Armonk N.Y., USA). Absolute numbers and simple percentages were used to describe categorical variables. Similarly, quantitative variables were described using measures of central tendency (mean, median) and measures of dispersion (range, standard deviation) as appropriate.

Results

The peak age of occurrence of all cancers was marginally between 46 and 60 years (32.3%), whereas 74.4% of the cancer cases occurred among the women of high parity [Table 1].

The mean age for cervical carcinoma patients (55.50 ± 12.71 years) was higher than that of uterine cancer (50.54 ± 515.18 years) and ovarian (42.34 ± 14.91 years) but lower than vulva cancer (63.50 ± 15.09) and the mean parity for cervical cancer (4.41 ± 2.05) was higher than those of uterine cancer (3.39 ± 2.25) and ovarian (2.94 ± 2.11) [Table 2].

The most common site for genital malignancy was on the cervix (52.7%), followed by ovarian cancer (28.1%), endometrial cancer (10.2%), choriocarcinoma (6.6%) and the least was vulva cancer (2.4%) [Table 3]. No case of vagina cancer was seen within the period.

The peak incidence for cervical cancers was between 31 and 45 years of age; both uterine and ovarian cancers plateauing at ages between 46 and 60 years and vulva cancer peaking at ages between 61 and 75 years [Table 4].

Majority (60.5%) of the gynecological cancer cases presented at advanced stages of the disease [Table 5] and the most common cause of death amongst cancer patients was renal failure.

Trend of prevalence of gynecological cancers in the study population [Figure 1] showed the initial sudden rise in prevalence rate of cervical cancer and reaching its peak in the year 2016 and a sharp decline, reaching lowest in 2018 and falling rate of ovarian cancer, slight fall in endometrial cancer, whereas vulva and choriocarcinoma did not significant change within this period.

The peak age of occurrence of all cancers was between 46 and 60 years (32.3%), followed by ages between 31 and 24 years (29.9%), whereas majority Para 5 and above (48.7%) and Paras 3–4 (25.7%) of the cancer cases occurred among the women of high parity.

The mean age for cervical carcinoma patients (55.50 ± 12.71 years) was higher than that of uterine cancer (50.54 ± 515.18 years) and ovarian (42.34 ± 14.91 years) but lower than vulva cancer (63.50 ± 15.09). The mean parity

### Table 1: Age range and parity distribution of the patients with the various cancers

| Age   | Frequency | Percent |
|-------|-----------|---------|
| 15-30 | 17        | 10.2    |
| 31-45 | 50        | 29.9    |
| 46-60 | 54        | 32.3    |
| 61-75 | 44        | 26.3    |
| 76-90 | 2         | 1.2     |
| Total | 167       | 100.0   |

| Parity | Frequency | Percent |
|--------|-----------|---------|
| 0      | 21        | 12.6    |
| 1-2    | 25        | 15.0    |
| 3-4    | 43        | 25.7    |
| >5     | 78        | 46.7    |
| Total  | 167       | 100.0   |

### Table 2: Sites of malignancies with mean age and mean parity of the distribution

| Site of malignancy | Mean age±SD | Mean parity±SD |
|--------------------|-------------|----------------|
| Cervix             | 55.50±12.71 | 4.41±2.05      |
| Uterus             | 50.54±15.18 | 3.39±2.25      |
| Ovary              | 42.34±14.91 | 2.94±2.11      |
| Vulva              | 63.50±15.09 | 5.50±2.38      |
| Overall mean       | 51.16±14.95 | 3.85±2.21      |

### Table 3: Site and frequency of distribution of female genital cancer

| Site of Tumor | No. of cases | Percent |
|---------------|--------------|---------|
| Cervix        | 88           | 52.7    |
| Uterus        |              |         |
| Endometrial   | 17           | 10.2    |
| Ovary         | 47           | 28.1    |
| Choriocarcinoma | 11         | 6.6     |
| Vulva         | 4            | 2.4     |
| Total         | 167          | 100.0   |

Figure 1: Trend of prevalent rate from 2014 to 2018
for cervical cancer (4.41 ± 2.05) was higher than those of uterine cancer (3.39 ± 2.25) and ovarian (2.94 ± 2.11), but lower than the vulva cancer (5.50 ± 2.38).

In Table 3, most (52.7%) had cervical cancer, followed by ovarian cancer (28.1%), endometrial cancer (10.2%), choriocarcinoma (6.6%), and the least was vulva cancer (2.4%).

Trend of prevalence of gynecological cancers in the study population [Figure 1] showed the initial sudden rise in prevalence rate of cervical cancer and reaching its peak in 2016 and a sharp decline in 2018, falling rate of ovarian cancer, slight fall in endometrial cancer, whereas vulva and choriocarcinoma did not significant change within this period.

### Discussion

In this study, gynecological cancers constituted 5.5% of all the gynecological admissions within the period. This is less than 8.4% and 10.7% documented by Agboeze et al. and Yakasai et al., respectively. The peak age of occurrence of all cancers was marginally between 46 and 60 years (32.3%) with overall mean age of 51.16 ± 14.95 years. This finding is comparable with mean age of 54.6 ± 14.2 years documented elsewhere.

The most common site for genital malignancy was on the cervix (52.7%). This finding of cervical cancer being the most common gynecological cancer is consistent with studies conducted in other places and comparable to work conducted elsewhere. It is, however, far less than 70.5%, 78%, and 81% that were recorded in Enugu, Orlu, and Maiduguri, respectively. In contrast, Jamal et al. in Pakistan documented ovarian cancer (42.4%) being the most common cause of all genital cancers, followed by cervical cancer. These findings indicate that the incidence of cervical cancer is still high in sub-Sahara Africa. In developing countries, due to low resources and lack of awareness there has not been much improvement in the screening program. Fortunately, there is a marked reduction in the incidence of cervical cancer in our center over the study period probably as a result improvement in screening exercise. To arrest the trend of cervical cancers, Government in developing countries must recognize cervical cancer as a major public health concern and allocate appropriate resources for its prevention and treatment. The mean age for cervical carcinoma patients in this study was 55.50 ± 12.71 years. This finding is similar to 57.5 ± 12.6 years documented by Iyoke et al. It is, however, higher than mean age of 46.25 ± 4.99 years reported by Yakasai et al.

Ovarian cancer constituted 28.1% for gynecological cancers accounting for the second most common in this study. This finding is similar to 21.1% and 20.6% documented in Enugu and Imo, respectively. It is however at variance with an earlier study that reported incidence of 2.66% in the same place and 8.2% documented in another place. The mean age at presentation was 42.34 ± 14.91 years. This is consistent with the findings of 45.4 ± 17.1 and 45.7 ± 4.3 years made in Enugu and Lagos, respectively. It is, however, lower than 57 ± 4.5 years reported in another study. This study revealed a highest case fatality rate with ovarian cancer and this is similar to reports by Okunade et al. This is probably due to their late presentations as present with nonspecific symptoms and there is no standard screening technique for early diagnosis of ovarian cancer. As it is difficult to detect early in its evolution when it is still curable, over 75% of patients already have advanced disease at diagnosis.

The endometrial cancer endometrial cancer accounted for 10.2% of the female genital cancers in this study and it is consistent with the findings of 10.1% by Joseph et al. in Abakiliki. This is comparable to findings of 11.8% and 13.3% reported in Enugu and Port Harcourt, respectively, but higher than 4.3% documented by Vijender et al. However, its prevalence is much lower than 30.5% that was recorded in Kano. The mean age for the endometrial cancer of 50.54 ± 15.18 years noted in this study was less than 62.4 ± 8.3 years cancers documented in Kano, but it is in agreement with the mean age of 56.1 ± 12.7 and 54 years as reported by Iyoke et al. and Muhammad et al. respectively.

In this study, choriocarcinoma is responsible for 6.6% of gynecological malignancies and it is comparable to 4.2% reported in other places. Contrary to these findings,

### Table 4: Age distribution according to site of malignancy

| Site        | 15-30 | 31-45 | 46-60 | 61-75 | 76-90 |
|-------------|-------|-------|-------|-------|-------|
| Cervix      | 0     | 31    | 28    | 27    | 2     |
| Uterus      | 4     | 6     | 10    | 8     | 0     |
| Ovary       | 13    | 12    | 16    | 6     | 0     |
| Vulva       | 0     | 1     | 0     | 3     | 0     |
| Total       | 17    | 50    | 54    | 44    | 2     |

### Table 5: Stage at presentation

| Stage | Frequency | Percent |
|-------|-----------|---------|
| 1     | 24        | 14.4    |
| 2     | 42        | 25.1    |
| 3     | 72        | 43.1    |
| 4     | 29        | 17.4    |
| Total | 167       | 100.0   |

The table shows that the majority of the gynecological cancer cases presented at advanced stages of the disease; 60.5% (between stages III and IV)
choriocarcinoma was found to be the second most common malignant tumor of female genital tract in Ibadan, Nigeria.[7]

It is worthy of note that this essentially affected the women only in their reproductive age group.

On the contrary, vulva cancer is the least and constituted 2.4% of gynecological cancer in this study. All the women affected in this study were of menopausal age and the mean age of occurrence was 63.50 ± 15.09 years. This is comparable to 58.7 ± 4.9 and 55 ± 6.3 reported in Enugu, Nigeria, and Burkina Faso, respectively.[3,23]

Majority (60.5%) of the gynecological cancer cases presented at advanced stages of the disease and this in comparable to 80% of the women noted to have presented at advanced stages (stages III and IV) in a study conducted by Okunade et al.[8] in Lagos. The perception of the general public not to seek for medical advice unless necessary, low level of awareness in our low-resource setting, absence or poor quality of screening programs, lack of health care providers and policy makers, limited access to health care services and poor referral system are attributed to be the cause of late presentation these patients.[7]

The most common cause of death among cancer patients in this study was renal failure unlike findings in another study that documented anemia as the most common sequelae of various cancer cases.[8]

**Conclusion**

Cervical cancer remains the most common gynecological cancer in Abuja, Nigeria; fortunately, the incidence is currently showing a downward trend probably due to improvement in cervical screening exercise. This is followed by ovarian cancer which is a major cause of case fatality and the preponderance of the gynecological cases presenting in advanced stage and the cause of mortality were mainly due to renal complications. Thus, education and public enlightenment on routine screening and treatment of premalignant lesions of female genital tract malignancies is the way forward.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Joseph A, Oliaemeka EP, Chukwudi OR, Igwe NM, Agwu MR, Egbuji CC. Frequency and pattern of gynecological cancers in federal teaching hospital, Abakaliki, Nigeria. J Basic Clin Reprod Sci 2015;2:54-7.
2. Vijender J, Adreena P, Garg K, Kiran M. Incidence of different malignancies in female genital tract: Study in 504 women in rural population. Int J Contemp Med Res 2015;4:77-83.
3. Iyoke CA, Ugwu G, Ezugwu EC, Ezeogu FO, Lawal OL, Oyebuchi AZ. Challenges associated with the management of gynecological cancers in a tertiary hospital in South East Nigeria. Int J Women’s Health 2014;6:123-30.
4. Ugwu EO, Iferikigwe ES, Okeke TC, Ugwu AO, Okiezie OA, Agu PU. Pattern of gynecological cancers in University of Nigeria teaching hospital, Enugu, South Eastern Nigeria. Niger J Med 2011;20:266-9.
5. Yakasai IA, Ugwu EA, Otubu J. Gynecological malignancies in Aminu Kano teaching hospital Kano: A 3 year review. Niger J Clin Pract 2013;16:63-6.
6. Elisabete W, France L. Malignant tumors of the female reproductive system. Saf Health Work 2012;3:166-80.
7. Okeke TC, Onah N, Ikeko LC, Ezenyeaku C. The frequency and pattern of female genital tract malignancies at the University of Nigeria teaching hospital, Enugu, Nigeria. Ann Med Health Sci Res 2013;3:345-8.
8. Mark Cline J. Neoplasm of the reproductive tract: The role of hormone exposure. ILAR J 2004;45:179-88.
9. Okunade KS, Okunola H, Okunowo AA, Anorlu RI. A five year review of ovarian cancer at a tertiary institution in Lagos, South-West, Nigeria. Niger J Gen Pract 2016;14:23-7.
10. Muhammad AA, Adekunle OO, Modupeola SO, Muhammad U, Zulaiha S, Abdullahi A. A diary of endometrial malignancies in Zaria, Northern Nigeria. Sub-Saharan Afr J Med 2017;4:43-6.
11. Missaoui N, Jaidene L, Abdullekader AB, Abdelkrim SB, Beizig N, Yaacoub LB, et al. Cancer of the corpus uteri in Tunisia: Epidemiology and clinicopathological features. Asian Pac J Cancer 2011;12:461-4.
12. Mary AD, Charles AA, Verna V. Vulva cancer in Ghana – Review of a hospital based data. Gynecol Oncol Rep 2017;20:108-11.
13. Prat J. Pathology of cancers of the female genital tract. Int J Gynaecol Obstet 2015;131 (Suppl 2): S132-45.
14. Mayun AA, Rafindindi AH, Shenu M. Choriocarcinoma in north western Nigeria: A histopathological review. Niger Postgrad Med J 2012;19:215-8.
15. Daniel CN, Ango IG, Nwobodo EI. Choriocarcinoma with cerebral metastasis presenting as a stroke-like lesion. Sahel Med J 2015;18(Suppl S1):16-9.
16. Umeh UA, Nwankwo TO, Ugwu EO, Aniebue U, Ozumba BC, Umeh CR. Trend of gynaecological malignancies in University of Nigeria Teaching Hospital Ikuza-Ozalla Enugu, Nigeria. Int J Med Health Dev 2018;23:284-8.
17. Seleby-Fubara O, Uozigwe SA. Pattern of primary female genital cancer in Port Harcourt, Nigeria: A 12-year review. Sahel Med J 2003;6:34-9.
18. Umeobika JC, Ikeka LC, Ezenyeaku CT, Ezeabialu UI, Ojiyi EC. Gynecological malignant tumors at Imo State University Teaching Hospital Orlu, South East Nigeria. Afr J Med 2012;16:63-6.
19. Kyari O, Ngadda H, Mairiga A. Malignant tumours of female genital tract in North East Nigeria. East Afr Med J 2015;92(Suppl 1):142-5.
20. Jamal S, Mamoon N, Moghali S. The pattern of gynaecological malignancies in 965 cases from Pakistan. Ann Saudi Med 2006;26:382-4.
21. Anorlu RI. Cervical cancer: The sub-Saharan African perspective. Reprod Health Matters 2008;16:41-9.
22. Pindiga UH, El-Nafety AU, Ekanem IA. Female genital malignancies in Maiduguri, Nigeria: A review of 328 cases. Trop J Obstet Gynaecol 1999;16:52-6.
23. Zongo N, Korsaga-Somé N, Gang-Ny AB, Ouangré E, Zida M, Ouedraogo AM, et al. Cancer of the vulva in Burkina Faso: A hospital-based case series. Infect Agents Cancer 2016;11:1-6.